Refractory Ovarian Carcinoma Recruiting Phase 2 Trials for Fluorouracil (DB00544)

IndicationStatusPhase
DBCOND0110942 (Refractory Ovarian Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05733000CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsTreatment